Publication Name	World Journal of Hepatology
Manuscript ID	25926
Country	France

Received	2016-03-26 15:58
Peer-Review Started	2016-03-26 21:29
To Make the First Decision	2016-05-23 10:04
Return for Revision	2016-05-25 19:08
Revised	2016-07-08 23:05
Second Decision	2016-09-05 09:44
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-09-18 14:17
Articles in Press	2016-09-18 14:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-11-09 18:20
Publish the Manuscript Online	2016-11-16 10:47

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Anti-hepatitis C virus drugs and kidney
Manuscript Source	Invited Manuscript
All Author List	Paul Carrier, Marie Essig, Marilyne Debette-Gratien, Denis Sautereau, Annick Rousseau, Pierre Marquet, Jérémie Jacques and Véronique Loustaud-Ratti
Funding Agency and Grant Number
Corresponding Author	Paul Carrier, MD, Service d’Hépato-gastroentérologie, CHU Limoges, 2, Avenue Martin Luther King, 87042 Limoges, France. pcarrier@hotmail.fr
Key Words	Nephrotoxicity; Hepatitis C; Direct anti-viral agents; Kidney; End-stage renal disease
Core Tip	Hepatitis C patients are clearly at risk of chronic kidney disease (CKD). New direct anti-viral agents (DAAs) with different pharmacokinetic properties are generally efficient in such populations. However, renal toxicity has been described in frail patients such as patients with CKD, transplants and human immuno-deficiency virus co-infections under real-life conditions, especially with sofosbuvir combinations. New DAAs, which will be soon approved, will probably change the landscape favorably. Close monitoring of renal function is required for at-risk patients, but patients without comorbidities are probably at a very low risk of renal toxicity.
Publish Date	2016-11-16 10:47
Citation	Carrier P, Essig M, Debette-Gratien M, Sautereau D, Rousseau A, Marquet P, Jacques J, Loustaud-Ratti V. Anti-hepatitis C virus drugs and kidney. World J Hepatol 2016; 8(32): 1343-1353
URL	http://www.wjgnet.com/1948-5182/full/v8/i32/1343.htm
DOI	http://dx.doi.org/10.4254/wjh.v8.i32.1343

Full Article (PDF)	WJH-8-1343.pdf
Full Article (Word)	WJH-8-1343.doc
Manuscript File	25926-Review.docx
Answering Reviewers	25926-Answering reviewers.pdf
Audio Core Tip	25926-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25926-Conflict-of-interest statement.pdf
Copyright License Agreement	25926-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	25926-Language certificate.pdf
Peer-review Report	25926-Peer-review(s).pdf
Scientific Misconduct Check	25926-Scientific misconduct check.pdf
Scientific Editor Work List	25926-Scientific editor work list.pdf